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OBJECTIVES: To develop the cost data infrastructure to
support a comprehensive, multi-national breast cancer
treatment decision-analysis model. The specifications re-
quired a user-friendly interactive interface for over 70
comparators composed of nearly 350 cost components
used in 24 unique decision trees. The model required an
ability to vary components readily and add new treat-
ments and cost components to multiple trees. METH-
ODS: Since standard decision-analysis software doesn’t
permit categorization of variables or application of the
same variable to multiple decision trees: (1) trees were
programmed in Visual Basic for the interactive interface,
and (2) cost data were loaded into a Microsoft ACCESS
database linked to the trees. Because of this structure, it
was possible to categorize cost data as: 1) Drug Acquisi-
tion and Administration, 2) Adverse Events/Complica-
tions, 3) Concomitant Medications, 4) Hospitalizations,
and 5) Monitoring Costs. For each country in the model,
a separate database was developed with country-specific
costs obtained from standardized databases, government
sources, published literature, and a provider survey. RE-
SULTS: This model was developed for six countries—US,
U.K., Germany, Japan, France, and Italy—and included
clinical and economic variables related to the diagnosis,
treatment, and outcomes of breast cancer. The structure
permits dynamic analyses via varying cost and probabil-
ity scenarios that reflect country-specific treatment prac-
tices and international variations. Each country’s cost da-
tabase applies to four distinct decision trees representing
different stages of breast cancer. The costs can be easily
summarized by category and modified so that multiple
cost components in multiple trees can be varied with one
edit. New cost components can be added to each coun-
try’s database and linked to the trees. CONCLUSION:
When constructing large models (such as disease models)
with several treatments having common cost components
in multiple decision trees, using a categorized cost data-
base linked to the treatment pathways will generate a
user-friendly model with easily-varied cost inputs.
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BACKGROUND: While treatment with 5-fluorouracil
(5-FU) plus leucovorin has been shown to prolong sur-
vival in patients with metastatic colorectal cancer, it also
can cause significant toxicity, sometimes necessitating
hospitalization. The incidence and costs of these admis-
sions have not been fully documented. OBJECTIVE: To
estimate the incidence and cost of hospitalizations for
toxicities associated with 5-FU therapy in patients with
metastatic colorectal cancer. METHODS: Using the
1994 Medicare 5% sample, we identified all patients
with metastatic colorectal cancer who underwent col-
orectal surgery. We stratified these selected subjects into
those who received 5-FU therapy within 90 days of their
surgery (“5-FU group”) and those who did not receive
any chemotherapy (“no-chemotherapy group”); patients
receiving chemotherapeutic agents other than 5-FU were
dropped from the sample. Using techniques of survival
analysis, we then compared the incidence and cost of all
hospital admissions with listed ICD-9-CM diagnosis
codes (principal or secondary) for conditions that may be
related to 5-FU toxicity (e.g., volume depletion, stomati-
tis, nausea and vomiting). RESULTS: A total of 441 pa-
tients met all study entry criteria, including 192 who re-
ceived 5-FU and 249 who did not receive chemotherapy
following surgery. 5-FU patients were significantly
younger than those in the no-chemotherapy group (p 
.001). Mean (SD) follow-up time was slightly longer in
the 5-FU group (137  96 days vs 117  88 days for no
chemotherapy). The incidence at 10.5 months of toxicity-
related hospitalizations (principally volume depletion,
agranulocytosis, gastroenteritis, and nausea and vomit-
ing) was 31% among patients who received 5-FU and
8% among those who did not receive chemotherapy. The
cost of inpatient care was $2,716 higher among 5-FU pa-
tients. CONCLUSIONS: Hospitalization for 5-FU toxic-
ity is frequent and costly among Medicare patients with
metastatic colorectal cancer.
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OBJECTIVES: Establish the impact that present chemo-
therapy management is having on the quality of life (qol)
of patients being treated at the Prince Charles Hospital;
Allow comparison of the effect on the patients qol be-
tween established treatment modalities; Allow compari-
son of the effects on patients qol between established and
future trial treatment protocols. We report the interim
findings of this ongoing quality of life study. METH-
ODS: All patients referred for chemotherapy manage-
ment of their non-small cell lung cancer (NSCLC) were
asked to participate. The EORTC QLQ 30 and LC 13
were used to assess patients qol when disease restaging
tests were conducted. Data was entered into an access da-
tabase that allowed comparison. Protocols used were
CIV, CV- adjuvant-neoadjuvant setting. CG and single
agent Gemcitabine 1000mg/m2 on days 1, 8, 15, in the
palliative setting. RESULTS: Patients ages ranged 39 to
73 yrs, average age 53 yr, median, 51, mode 47years. The
sample consisted of 3 females & 12 males, 6 patients are
not reported, 3 neoadjuvant had progressive disease after
two cycles and were not followed, 3 palliative patients
died after one cycle of treatment. Of the 21 patients
treated 15 (71%) had improved Quality of Life scores
paralleled other measures of assessment. Scans show re-
sponse to single agent Gemzar in the palliative setting
and response to CIV in the neoadjuvant setting. CON-
CLUSION: we demonstrated 71% of our patients had
qol improvements. Management of patients with NSCLC
should consider chemotherapy. FUTURE DIRECTION:
An outcomes study is being conducted at two campuses
in Brisbane. This study seeks to include all newly diag-
nosed lung cancer patients and follow their progress
through their disease using clinical Quality of Life and
economic criteria to determine outcome. Comparison be-
tween treatment and within treatment arms will be com-
pared.
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OBJECTIVE: To critically evaluate the quality of health-
related quality of life (HRQoL) instruments for use in
clinical trials of non-small cell lung cancer (NSCLC).
METHODS: A structured review of literature was
conducted by searching MEDLINE (1975–2000) and
PsycINFO (1977–2000) using the keywords “lung can-
cer”, “quality of life” and “questionnaire”, and manu-
ally. HRQoL instruments that had been used in or de-
signed for lung cancer were selected for review. Each
instrument was assessed for its general features, feasibil-
ity, scoring and interpretation, and psychometric proper-
ties. RESULTS: Ten instruments were selected for review:
EORTC-QLQ30, EORTC-LC13, FACT-L, LCSS, FLIC,
CARES, CARES-SF, RSCL, FLIC and MQOL. Most
questionnaire items were appropriately generated through
multiple cycles of input from patients and clinicians. The
most studied psychometric properties were internal con-
sistency and convergent/divergent validity, with most in-
struments having Cronbach’s a 0.7 and acceptable cor-
relation coefficients for convergent/divergent validity.
Responsiveness, interpretability of the scale score, and
validity testing in cross-cultural settings were either inad-
equately evaluated or missing. All instruments have a
good readability level, an administration time less than
20 minutes, a time horizon of one week or less, and are
multilingual. All questionnaires have been used in clinical
trials for non-small cell lung cancer except CARES,
CARES-SF and MQOL. CONCLUSIONS: There are sev-
eral reliable and validated HRQoL instruments that are
appropriate for use in clinical trials of NCSLC. In partic-
ular, the EORTC-QLQ30 and its lung cancer supple-
ment, the LC13, LCSS, RSCL, FACT-L, and CARES
have greater evidence of good psychometric properties.
Further research is required to evaluate the cross-cultural
performance, score interpretability and correlation with
clinical outcomes of these instruments.
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BACKGROUND: Cancer of the head and neck is the
11th most common cancer in the US, however, there are
no published, comprehensive studies examining the costs
associated with the treatment of head and neck cancer in
the United States. The objective of this research was to
design a model to estimate the cost of treatment for squa-
mous cell carcinoma of the head and neck (SCCHN).
METHODS: A decision analytic model was designed to
project the outcomes and costs associated with SCCHN.
The model was stratified by site of disease, stage of pre-
sentation, treatment, and outcome. The most common
therapeutic options for SCCHN were modeled: 1) sur-
gery, 2) radiation therapy, 3) surgery and radiation ther-
apy, 4) radiation therapy and chemotherapy, and 5) palli-
ation. Base case data were obtained from the National
Cancer Data Base, the published literature, a modified
Delphi survey of experts, and an analysis of the Medicare
Standard Analytic Files. RESULTS: Average per patient
cost of care for SCCHN in the US was estimated to be
$20,876. Higher costs resulted for patients that present
with advanced cancers. The estimated cost of treating a
patient with Stage IV lip SCC ($19,274) was four times
that of Stage 0 lip SCC ($5,062). The site with the lowest
cost of treatment was lip ($7,261) while the highest cost
was associated with hypopharyngeal SCC ($28,584). The
cost per patient for palliative care ranged from $2,052
for lip SCC (28% of total cost of care) to $7,172 for si-
